EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof‐of‐Concept Study with Alectinib

Ma Ida Mohmaed Ali iD, Lisa T van der Heijden iD, Matthijs Tibben, Hilde Rosing iD, Raween Kalicharan iD, Gerrina Ruiter iD, Jos H Beijnen iD, Hinke Huisman-Siebinga iD, Alwin D R Huitema iD, Neeltje Steeghs iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Ma Ida Mohmaed Ali und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Piperidines, Carbazoles, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traditional drug‐food interaction studies of oral anticancer agents have a high patient burden. A patient‐friendly alternative approach to studying food effects could be the use of stable isotopically labeled microtracers. A prospective, single‐center, open‐label, crossover, food effect study with the microtracer 2 H 6 ‐alectinib was conducted in patients with ALK‐positive, non‐small cell lung cancer treated with 600 mg alectinib bidaily. On occasion 1 (fed state), patients received 100 μg 2 H 6 ‐alectinib in addition to their usual dose of alectinib and a standardized Dutch breakfast (320–392 kcal and 7.5–7.8 g fat). On occasion 2 (fasted state), patients received 2 H 6 ‐alectinib and alectinib after overnight fasting. Pharmacokinetic (PK) samples were collected up to 8 hours after intake of 2 H 6 ‐alectinib. The effect of food on relative bioavailability (F) and mean transit time of 2 H 6 ‐alectinib was assessed by population PK modeling. Differences in area under the plasma concentration‐time curve (AUC) and maximum concentration ( C max ) between fed and fasted states were estimated by simulations. MTT in the fed state was 3.14 hours (relative standard error (RSE): 16.0%). MTT and F in the fasted state were 28% (RSE: 20.5%) and 35% (RSE: 12.4%) lower, respectively, compared to the fed state. The geometric mean ratio (fed vs. fasted) of AUC and C max was 1.52 (90% confidence interval (CI): 1.25–1.89) and 1.42 (90% CI: 1.16–1.76), respectively. These results showed that the intake of a Dutch breakfast leads to a higher total exposure of alectinib. More importantly, the feasibility of a microtracer food effect study to reduce patient burden was demonstrated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesCarbazolesCarcinoma, Non-Small-Cell LungLung NeoplasmsFood-Drug InteractionsAntineoplastic AgentsProtein Kinase InhibitorsHumansMaleMiddle AgedFemaleCross-Over StudiesAgedProspective StudiesProof of Concept StudyAdultBiological AvailabilityAdministration, OralIsotope LabelingArea Under Curve

Substanzen

alectinibPiperidinesCarbazolesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Division of Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Clinical Pharmacy, OLVG, Amsterdam, The Netherlands.
  • Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Division of Pharmaco-Epidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.

ORCID-Profile: Ma Ida Mohmaed Ali, Lisa T van der Heijden, Hilde Rosing, Raween Kalicharan, Gerrina Ruiter, Jos H Beijnen, Hinke Huisman-Siebinga, Alwin D R Huitema, Neeltje Steeghs

Zitieren

APA

Mohmaed Ali, M. I., van der Heijden, L. T., Tibben, M., Rosing, H., Kalicharan, R., Ruiter, G., Beijnen, J. H., Huisman-Siebinga, H., Huitema, A. D. R., & Steeghs, N. (2026). Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof‐of‐Concept Study with Alectinib. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70141

Vancouver

Mohmaed Ali MI, van der Heijden LT, Tibben M, Rosing H, Kalicharan R, Ruiter G, et al. Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof‐of‐Concept Study with Alectinib. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70141

BibTeX
@article{MohmaedAli2026,
  author = {Mohmaed Ali, Ma Ida and van der Heijden, Lisa T and Tibben, Matthijs and Rosing, Hilde and Kalicharan, Raween and Ruiter, Gerrina and Beijnen, Jos H and Huisman-Siebinga, Hinke and Huitema, Alwin D R and Steeghs, Neeltje},
  title = {Reducing the Burden of Interaction Studies in Cancer Patients Using a Stable Isotopically Labeled Microtracer: A Proof‐of‐Concept Study with Alectinib},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70141}
}
Kostenlos starten →